Clinical trial · Observational
A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
A Study On The Prediction of Neoadjuvant Efficacy And Heterogeneity For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study employed MR cytometry imaging combined with deep-radiomic research methods to predict the heterogeneity of rectal cancer, and constructed a model to predict the sensitivity to neoadjuvant therapy and potential mechanisms, assisting clinicians in early identification of high-risk tumors and patients with treatment-susceptible rectal cancer, and selecting individualized treatment plans, thereby improving patient prognosis. To this end, the investigators need to collect the clinical diagnosis and treatment data of patients, surgical and biopsy pathological information, pre-treatment rectal MRI images and colonoscopy biopsy tissue sections, and follow up on the surgical pathological results and recurrence of patients. This study is a non-interventional diagnostic study, which does not interfere with the routine diagnosis and treatment of patients, does not affect any medical rights of patients, and does not increase any medical risks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer, Adenocarcinoma | Malignant Rectal Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Pathological complete response
- timeFrame
- One month after surgery
- measure
- Pathological tumor regression grade
- timeFrame
- One month after surgery
- measure
- progression-free survival
- timeFrame
- From date of surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Secondary outcomes (1)
- measure
- Pathological differentiation grade
- timeFrame
- One month after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed rectal adenocarcinoma without previous treatment * Complete radical surgery in the institute * Complete rectal MRI within 2 weeks before surgery Exclusion Criteria: * Concomitant malignancies or systemic disease * Inadequate MR image quality for analysis * Incomplete clinicopathological data * Loss of follow-up
References
Publications (1)
- DERIVEDZhao Q, Shi D, Zhong H, Jin C, Wang Z, Shi Z, Li L, Wang B, Jiang Y, Feiweier T, Xu J, Guo H, Zhang H. The predictive value of MR cytometry in histological differentiation of rectal cancer: an exploratory study. Eur Radiol. 2026 Jun;36(6):5155-5168. doi: 10.1007/s00330-026-12341-w. Epub 2026 Jan 30. PMID 41617831